Exelixis Inc EXEL
News
Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda
Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm
FDA Extends Review of Exelixis' Zanzalintinib in Colorectal Cancer
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September
Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories
Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm
Exelixis (EXEL) Securities Investigation Notice - Levi & Korsinsky
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law
EXEL Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Exelixis (EXEL)
EXEL SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Exelixis
Exelixis Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Exelixis (EXEL)
Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update

